Mirdametinib
Last Updated: 02/24/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 42 publications
Hidden-driver inference reveals synergistic brain-penetrant therapies for medulloblastoma.
Journal: bioRxiv : the preprint server for biology
Published: December 03, 2025
FDA approval of mirdametinib for NF1-associated plexiform neurofibromas: clinical and regulatory perspectives.
Journal: Annals of medicine and surgery (2012)
Published: October 13, 2025
Mirdametinib, an FDA-Approved MEK1/2 inhibitor for adult and pediatric NF1-associated plexiform neurofibromas.
Journal: Expert opinion on investigational drugs
Published: September 11, 2025
Head-to-head preclinical treatment design prioritizes promising therapies for neurofibromatosis type 1 optic glioma clinical translation.
Journal: Neuro-oncology advances
Published: August 04, 2025
Mirdametinib: FDA approved MEK inhibitor for neurofibromatosis type 1.
Journal: Cancer chemotherapy and pharmacology
Published: July 17, 2025
Comment on: "selumetinib use as targeted therapy for plexiform neurofibroma: a comprehensive review of the literature" - mirdametinib as the emerging standard in NF1-PN.
Journal: Orbit (Amsterdam, Netherlands)
Published: July 09, 2025
Selumetinib in Adult Neurofibromatosis 1 with Plexiform Neurofibroma.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: June 21, 2025
Combination of the Novel RAF Dimer Inhibitor Brimarafenib With the MEK Inhibitor Mirdametinib Is Effective Against NRAS Mutant Melanoma.
Journal: Pigment cell & melanoma research
Published: May 12, 2025
High-content microscopy and machine learning characterize a cell morphology signature of NF1 genotype in Schwann cells.
Journal: bioRxiv : the preprint server for biology
Published: April 28, 2025
Fibroblasts Attenuate Anti-Tumor Drug Efficacy in Tumor Cells via Paracrine Interactions with Tumor Cells in 3D Plexiform Neurofibroma Cultures.
Journal: Cells
Published: April 23, 2025
Mirdametinib (Gomekli) for neurofibromatosis type 1.
Journal: The Medical letter on drugs and therapeutics
Published: April 20, 2025
Last Updated: 02/24/2026